【新闻】有关治疗乳腺癌的药

来源: 2020-09-15 11:09:44 [] [博客] [旧帖] [给我悄悄话] 本文已被阅读: 次 (5217 bytes)

Bayer Signs $25 Million License Agreement With US Company to Develop Breast Cancer Drug

   By Cecilia Butini 
 

Bayer AG said Tuesday that it has entered a license agreement with U.S.-based biotechnology company Systems Oncology LLC to develop and commercialize its breast cancer drug ERSO with an upfront payment of $25 million.

Under the agreement, the German chemical and pharmaceutical conglomerate will also grant Systems Oncology commercialization milestone payments for a total of $345 million, it said, plus payments upon achievement of certain development and royalties on future global net sales.

ERSO is a compound currently in pre-clinical development which can be used for the treatment of metastatic Estrogen Receptor-positive breast cancer, Bayer said.

It added that the drug could represent a novel treatment option for patients with this type of cancer, given that there are only limited options available so far for patients with progressed forms of the disease.


 

Write to Cecilia Butini at cecilia.butini@wsj.com

加跟帖:

  • 笔名:      密码: 保持登录状态一个月,直到我退出登录。
  • 标题:
  • 内容(可选项): [所见即所得|预览模式] [HTML源代码] [如何上传图片] [怎样发视频] [如何贴音乐]
回到顶部